Findings

What do systematic reviews say?

10 questions · 10 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 30%Moderate 3 · 30%High 4 · 40%

Topotecon vs Topotecon+thalidomide

Overall response · patients with EOC

Topotecon may leads to lower overall response compared with topotecon+thalidomide (low certainty).

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
RR 0.47 [0.23, 0.99]
1 study · 75 participants
Low

Topotecon vs PLD alone

Survival Hazard Ratio (platium‐sensitive) · patients with EOC

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
no estimate extracted
1 study · 220 participants
Moderate

Topotecon vs PLD alone

Survival Hazard Ratio (Platium‐resistant) · patients with EOC

Topotecon showed no clear difference in survival Hazard Ratio (Platium‐resistant) compared with PLD (low certainty).

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
RR 0.69 [0.35, 1.38]
1 study · 255 participants
Low

Topotecon vs PLD alone

Progression free survival (platium‐sensitive) · patients with EOC

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
no estimate extracted
1 study · 220 participants
Moderate

Topotecon vs PLD alone

Progression free survival (platium‐resistant) · patients with EOC

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
no estimate extracted
1 study · 220 participants
Moderate

Topotecon vs 175 mg/m2 paclitaxel

SurvivalScale from: 1 to 226.3. · patients with EOC

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
no estimate extracted
1 study · 226 participants
High

Topotecon vs 175 mg/m2 paclitaxel

Time to progressionScale from: 1 to 137.3. · patients with EOC

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
no estimate extracted
1 study · 226 participants
High

Topotecon vs Topotecon+thalidomide

Progression‐free survival · patients with EOC

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
High

Topotecon+Carboplatin+Paclitaxel vs Carboplatin+Paclitaxel

Overall Survivalclinical observation · patients with ovarian cancer

Topotecon+Carboplatin+Paclitaxel showed no clear difference in overall Survivalclinical observation compared with carboplatin+Paclitaxel (high certainty).

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
HR 1.02 [0.97, 1.06]
2 studies · 1998 participants
High

Topotecon+Carboplatin+Paclitaxel vs Carboplatin+Paclitaxel

Progression‐free survival · patients with ovarian cancer

Topotecon+Carboplatin+Paclitaxel may leads to higher progress free survival compared with carboplatin+Paclitaxel (low certainty).

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
HR 1.03 [1.03, 1.03]
2 studies · 1998 participants
Low